BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-22@catalystbrief.girapphe.com
DTSTAMP:20261117T061546Z
LAST-MODIFIED:20261117T061546Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: RHEACELL GmbH & Co. KG — allo-APZ2-CVU [Apr 2027]
DESCRIPTION:Phase 3 primary completion: Allogeneic ABCB5-positive Dermal Me
 senchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)
 .\nSource: https://clinicaltrials.gov/study/NCT06489028\nhttps://catalystb
 rief.girapphe.com/e/22?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/22?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
